We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Reconstituted HDL-siRNA Nanoparticles Block Cancer Growth in Mouse Models

By LabMedica International staff writers
Posted on 12 Apr 2011
Synthetic HDL (high-density lipoprotein) nanoparticles loaded with small interfering RNA (siRNA) have been used to inhibit growth of tumor cells in mouse models of ovarian and colorectal cancer.

Investigators at the University of Texas MD Anderson Cancer Center (Houston, USA) have been seeking an effective and nontoxic means for introducing gene-silencing miRNA into cancer cells. More...
In this study, they exploited the need for cancer cells to take up large quantities of HDL through the SR-B1 receptor, which is overexpressed by many types of tumors. The only normal cells expressing this receptor are in the liver.

The investigators reported in the April 2011 issue of the journal Neoplasia that they had succeeded in establishing a novel formulation of siRNA by incorporating it into reconstituted high-density lipoprotein (rHDL) nanoparticles. They demonstrated that rHDL nanoparticles facilitated highly efficient systemic delivery of siRNA in vivo, mediated by the SR-B1 receptor. These nanoparticles were effective in silencing the expression of two proteins that are key to cancer growth and metastasis (signal transducer and activator of transcription 3 [STAT3] and focal adhesion kinase [FAK]) in mouse models of ovarian and colorectal cancer.

"RNA interference has great therapeutic potential but delivering it to cancer cells has been problematic,” said senior author Dr. Anil Sood, professor of cancer biology at the MD Anderson Cancer Center. "Combining siRNA with HDL provides an efficient way to get these molecules to their targets. If siRNA is not in a nanoparticle, it gets broken down and excreted before it can be effective. HDL is completely biocompatible and is a safety improvement over other types of nanoparticles. This study has several important implications in the ability to fight certain cancers.”

"In order to help expedite the study's progress to a clinical setting, we have identified 12 genes as biomarkers for response to STAT3-targeted therapy,” said Dr. Sood. ”Next, we will work with the [US] National Cancer Institute Nanoparticle Characterization Lab (Frederick, MD, USA) to develop a formulation of the HDL/siRNA nanoparticle for human use.”

Related Links:
University of Texas MD Anderson Cancer Center
National Cancer Institute Nanoparticle Characterization Lab



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Drug Test Kit
DrugCheck 3000
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.